A Study to Evaluate the Drug Levels, Metabolism, and Removal of BMS-986322 in Healthy Adult Male Participants

Bristol-Myers Squibb (BMS)

Status and phase: Completed; Phase 1

Conditions: Healthy Male Participants

Treatments: Drug: BMS-986322

Study type: Interventional

Funder types: Industry

Identifiers

NCT06088264

IM032-1018

Details and patient eligibility

About

The purpose of this study is to evaluate the drug levels, metabolism, and removal of BMS-986322 in healthy adult male participants.

Enrollment: 8 patients

Sex: Male

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Participants must have a body mass index of 18.0 to 32.0 kg/m2, inclusive.
• Participants will be required to always use a latex or other synthetic condom with spermicide during any sexual activity
• Participants must refrain from donating sperm during the entire study and for at least 90 days from dose of study drug.

Exclusion criteria

• Participant must not have had any clinically significant diagnostic or therapeutic radiation exposure within the previous 12 months prior to admission to the clinic.
• Participant must not be currently employed in a job requiring radiation exposure monitoring.
• Participant must not have had any major surgery within 4 weeks of study drug administration that could impact upon the absorption of study drug

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

8 participants in 1 patient group

Administration of BMS-986322

Experimental group

Treatment:

Drug: BMS-986322